LaunXP will pay Apollomics $10m upfront within 60 days of the agreement date. Apollomics is also qualified for potential ...

PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel ...

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...

The FDA has approved Egrifta WR, a concentrated formulation (F8) of tesamorelin, for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

14 Centre for Liver and Gastroenterology research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK 15 NIHR Biomedical Research Centre, University of Birmingham and ...